Johnson & Johnson Receives FDA Authorization for Ottava Robotic Surgery System

What happened

The FDA granted de novo marketing authorization for Johnson & Johnson's Ottava robotic surgical system for use in multiple general surgery procedures. The authorization covers procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy (gallbladder removal), splenectomy, gastric sleeve surgery, small bowel resection, appendectomy, fundoplication, hiatal hernia repair, and lysis of adhesions. The FDA clearance came approximately six months after J&J's initial submission, meeting the company's projected timeline of approval before year-end. Ottava is the world's first table-integrated soft-tissue robotic system, incorporating four robotic arms into a standard-size surgical table. J&J stated it would begin a phased U.S. commercial launch with select customers while working to expand into additional indications and regulatory markets. A U.S. clinical trial for inguinal hernia repair is also underway.

Why it matters

The authorization allows Johnson & Johnson to formally enter the soft-tissue robotic surgery market, a sector historically dominated by established competitors. Ottava's table-integrated design takes up 30% to 50% less space than traditional boom- and cart-mounted systems, potentially addressing operating room efficiency concerns for hospitals. The system features synchronized table and robotic arm motions to facilitate patient repositioning and multi-quadrant anatomical access, along with instrument innovations for commonly used surgical tools and digital platform integration for surgical data. This positions J&J to offer hospitals an alternative robotic platform with a differentiated footprint and workflow design. The authorization represents a significant milestone for J&J's medtech division, enabling the company to compete directly in the growing surgical robotics segment while building a foundation for future indication expansions.

Bigger picture

The Ottava authorization positions Johnson & Johnson as the second major medtech company to enter the U.S. soft-tissue robotic surgery market, following Medtronic's FDA clearance in late 2025. This breaks more than two decades of limited competition in the sector. Additionally, smaller companies including CMR Surgical, Distalmotion, and Moon Surgical are also launching robotic systems in the U.S., creating a more competitive landscape. Industry analysts remain cautious about near-term market share shifts, noting that Ottava's launch will require deliberate phasing, significant physician and staff training, and time to expand indications. However, the authorization allows J&J to establish a presence in surgical robotics and iterate on the platform over time, potentially building toward a broader competitive offering in a market expected to play an increasingly important role in surgical care.

What to watch

Monitor the pace and scope of Ottava's U.S. commercial rollout with select hospital customers, including early adoption rates and customer feedback on operating room efficiency gains. Track results from the ongoing U.S. clinical trial for inguinal hernia repair, which could expand Ottava's indication portfolio. Watch for regulatory submissions and approvals in international markets as J&J works to expand geographic availability. Follow J&J's timeline for securing additional surgical indications beyond general surgery, which would broaden Ottava's competitive positioning. Observe competitive responses from established robotic surgery providers and market share trends as multiple new entrants scale their commercial efforts.